** Shares of drug developer FibroGen FGEN.O jump 79.7% to $1.01 premarket
** FGEN says it is selling its China unit to AstraZeneca AZN.L for about $160 mln
** Deal includes an enterprise value of $85 mln plus FibroGen net cash held in China at closing, estimated at about $75 million
** Deal expected to close by mid-2025
** AZN will obtain all rights to anemia drug, roxadustat, in China, while FibroGen retains rights to roxadustat in the U.S. and other markets
** FGEN plans to have an FDA meeting in Q2 2025 to determine next steps for roxadustat development in the U.S.
** Deal will extend FGEN's cash runway into 2027, co says
** FGEN fell ~36% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。